You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

BEXSERO: Mechanism of action 1*

BEXSERO was developed using a multiple antigen approach. Immunization with BEXSERO is intended to raise the titer of bactericidal antibodies that specifically bind the vaccine antigens fHbp, NadA, NHBA, and PorA P1.4 (the immunodominant antigen present in the OMV component). 1*

Factor H binding protein

Neisserial adhesin A

Neisseria Heparin Binding Antigen

Outer Membrane Vesicles that contain PorA 1.4

* Clinical significance unknown.


  1. BEXSERO Product Monograph. March 31, 2022.

This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit our consumer website